IXEMPRA (ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The epothilones are isolated from the myxobacterium Sorangium cellulosum.
IXEMPRA (ixabepilone) is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting.
IXEMPRA is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.
Media Articles Related to Ixempra (Ixabepilone)
'Chemo Brain' Lasts for Months in Many Breast Cancer Survivors
Source: MedicineNet Depression Specialty [2017.01.12]
Title: 'Chemo Brain' Lasts for Months in Many Breast Cancer Survivors
Category: Health News
Created: 1/11/2017 12:00:00 AM
Last Editorial Review: 1/12/2017 12:00:00 AM
New insights into mechanisms of breast cancer development and resistance to therapy
Source: Breast Cancer News From Medical News Today [2017.01.11]
Why does breast cancer develop and how come certain patients are resistant to established therapies?
Obamacare Boosts Breast Cancer Screening, Study Finds
Source: MedicineNet Colon Cancer Specialty [2017.01.10]
Title: Obamacare Boosts Breast Cancer Screening, Study Finds
Category: Health News
Created: 1/9/2017 12:00:00 AM
Last Editorial Review: 1/10/2017 12:00:00 AM
'Overdiagnosis Exists in Breast Cancer'
Source: Medscape Hematology-Oncology Headlines [2017.01.09]
Another study provides evidence supporting the idea that breast cancer screening results in overdiagnosis of disease, and a new editorial provides historical perspective on how this came about.
Medscape Medical News
Spread of triple-negative breast cancer could be halted with existing drug
Source: Biology / Biochemistry News From Medical News Today [2017.01.09]
Researchers find a class of drugs used to treat estrogen receptor-positive breast cancer might also reduce the spread of triple-negative breast cancer.
Published Studies Related to Ixempra (Ixabepilone)
Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. [2011.02]
Patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes often have decreased performance status secondary to extensive tumor involvement. Here, we report the pooled analysis of efficacy and safety data from two similarly designed phase III studies to provide a more precise estimate of benefit of ixabepilone plus capecitabine in MBC patients with Karnofsky's performance status (KPS) 70-80...
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. [2010.07.10]
PURPOSE: We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared with capecitabine alone in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes... CONCLUSION: This study confirmed a previous trial demonstrating improved PFS and response for the ixabepilone-capecitabine combination compared with capecitabine alone, although this did not result in improved survival.
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. [2010.07]
Limited proven treatment options exist for patients with metastatic breast cancer (MBC) resistant to anthracycline and taxane treatment.A clinical benefit was also seen in patients in the KPS 70-80 subgroup.
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. [2009.11]
Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer...
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. [2009.05.01]
PURPOSE: Using data from a recent randomized trial, we evaluated the cost effectiveness of ixabepilone plus capecitabine versus capecitabine alone in patients with predominantly metastatic breast cancer considered to be taxane-resistant and previously treated with or resistant to an anthracycline... CONCLUSION: Addition of ixabepilone to capecitabine adds approximately $31,000 to overall medical costs and affords approximately 1 additional month of quality-adjusted survival.
Clinical Trials Related to Ixempra (Ixabepilone)
Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer [Completed]
The purpose of this study is to determine the maximum tolerated dose, dose-limiting
toxicity, and recommended Phase II dose of ixabepilone in combination with carboplatin in
patients with non-small cell lung cancer.
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma [Enrolling by invitation]
Endometrial cancer (EC) is the 8th most common female cancer in Taiwan. Its incidence is
increasing in the recent few years, around 1,200 new cases per year. The outcome of
recurrent EC is disappointing, except focal recurrences that could be irradiated or removed.
Chemotherapy is currently the most common salvage treatment for recurrent endometrial
cancer. However, the response rate (RR) to 2nd-line treatment is approximately 0-27. 3%, with
short median time to progression, 2-3. 9 months and low overall survival, 6. 4-11 months.
Due to progress of studies on the molecular and genetic basis of cancer and cellular
signaling pathways, targeted therapy has been developed for various cancer treatments. A
Gynecologic Oncology Group study found 44% of advanced endometrial cancer had HER>=2+ and
the ratio of HER2: chromosome 17 (CEP17) >=2. Another study showed that HER>=2+ was seen in
47% of carcinosarcoma. These evidences indicated HER2 gene amplification and HER2
overexpression occur in endometrial cancer and carcinosarcoma, especially in those of high
grade and recurrence. Lapatinib (L), an oral inhibitor of both EGFR(epidermal growth factor
receptor) and HER2(human epidermal growth receptor), has been shown to be an effective
treatment in HER2/neu overexpressing metastatic breast cancer. Ixabepilone is a
semisynthetic analog of the natural product epothilone B, and recently has been approved by
US Food and Drug Administration as a treatment option in metastatic breast cancer. It was
also observed that lapatinib + ixabepilone killed more breast tumor cells than trastuzumab +
paclitaxel in vitro. Two GOG(Gynecologic Oncology Group) studies had reported that weekly
Ixabepilone as 2nd-line chemotherapy provided a similar RR to 3-weekly regimen of 14. 3% in
platinum- and taxane-resistant epithelial ovarian cancer with less severe toxicities. The
combination of lapatinib and ixabepilone is expected to become an effective treatment for
recurrent endometrial cancer and carcinosarcoma, but the ideal dose is yet to be surveyed.
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer [Completed]
This study will determine the maximum tolerated dose of oral ixabepilone administered for 5
successive days every 21 days in participants with advanced cancer. The safety,
tolerability, and pharmacokinetics of ixabepilone in the body will be studied. In addition,
this study will assess preliminary evidence of the effect of food and famotidine on the
pharmacokinetics of oral ixabepilone.
Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer [Completed]
The purpose of this study was to estimate the response rate of ixabepilone monotherapy, and
the combination of ixabepilone plus cetuximab as first-line treatment of female subjects
with triple negative (estrogen receptor [ER], progesterone receptor [PR], Human Epidermal
Growth Factor Receptor 2 [HER2] negative) locally advanced non-resectable and/or metastatic
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer [Completed]